• Skip to main content
  • Skip to primary sidebar
Pediatric Pulmonology: The Remaining Barriers to Normalcy in Cystic Fibrosis

The Remaining Barriers to Normalcy in Cystic Fibrosis

  • Issues
  • Resources
  • About
  • Contact
  • Search

CFTR, bicarbonate, and the pathophysiology of cystic fibrosis

By Drucy Borowitz MD

The gene that encodes for the cystic fibrosis transmembrane regulator protein (CFTR) was identified in 1989, yet major pathophysiologic questions remain unanswered. There is emerging evidence that CFTR is a bicarbonate channel, a driver of chloride‐bicarbonate exchange and through its action on local pH, a regulator of other ion channels and of proteins that function optimally in a neutral environment. In both the respiratory and gastrointestinal (GI) tracts, bicarbonate drives ionic content and fluid on epithelial surfaces, allows mucins to unfold and become slippery, and contributes to innate immunity. In the GI tract bicarbonate neutralizes gastric acid to support digestion and absorption. When CFTR is dysfunctional, lack of bicarbonate secretion disrupts these normal processes and thus leads directly to the clinical symptoms and signs of CF. This article synthesizes evidence from cell, animal, and human investigations that support these concepts. Bicarbonate secretion does not seem to be the same in all tissues and varies with physiologic demand. Thus, tissue type and whether conditions are baseline or stimulated needs to be taken into account when evaluating the evidence concerning the role of bicarbonate in the pathophysiology of CF as a regulator of local pH. Basic and applied research that focuses on the role of CFTR‐mediated bicarbonate secretion helps explain many of the diverse clinical manifestations that are CF. Pediatr Pulmonol. 2015; 50:2S4–S30. © 2015 Wiley Periodicals, Inc.

Read the Full Article  

Journal Issue: The Remaining Barriers to Normalcy in Cystic Fibrosis I

Primary Sidebar

PP Cover - November 2018

Pediatric Pulmonology

The Remaining Barriers to Normalcy in Cystic Fibrosis I

October 2015 · View Articles

The Remaining Barriers to Normalcy in Cystic Fibrosis II

October 2016 · View Articles

The Remaining Barriers to Normalcy in Cystic Fibrosis III

November 2017 · View Articles

The Remaining Barriers to Normalcy in Cystic Fibrosis IV

November 2018 · View Articles

The Remaining Barriers to Normalcy in Cystic Fibrosis V

November 2019 · View Articles

The Remaining Barriers to Normalcy in Cystic Fibrosis VI

February 2021 · View Articles

The Remaining Barriers to Normalcy in Cystic Fibrosis VII

February 2022 · View Articles

Most Viewed Articles

  • Rapid therapeutic advances in CFTR modulator science

  • Reevaluating approaches to cystic fibrosis pulmonary exacerbations

  • Breakthrough therapies: Cystic fibrosis (CF) potentiators and correctors

  • Recent advances in the early treatment of cystic fibrosis: Bridging the gap to highly effective modulator therapy

  • Inflammation in cystic fibrosis: An update

Quiz and Survey

Test your knowledge and help shape future editions of "The Remaining Barriers to Normalcy." Participate in our Quiz and Survey »

This website is made possible by an educational grant from Vertex Pharmaceuticals Incorporated.

Vertex

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2018-2025 John Wiley & Sons, Inc. All Rights Reserved.
The content on this site is intended for health professionals.
Wiley